Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 17/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 12/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827569 | 0.86 | HIF1A (0.54) | HIF1AEPAS1HSP90AA1COXFA4 | |
| SCHEMBL2825117 | 0.81 | HIF1A (0.52) | HIF1AEPAS1HSP90AA1COXFA4ALDH1A1 | |
| Eulatachromene SCHEMBL9033640 | 0.75 | HIF1A (0.53) | HIF1AEPAS1COXFA4ALDH1A1CYP3A4 | |
| SCHEMBL5868243 | 0.73 | HIF1A (0.54) | HIF1AEPAS1COXFA4ALDH1A1CYP3A4 | |
| SCHEMBL9032911 | 0.73 | HIF1A (0.54) | HIF1AEPAS1 | |
| SCHEMBL16011689 | 0.73 | HIF1A (0.47) | HIF1AEPAS1 | |
| SCHEMBL4471596 | 0.72 | HPGD (0.50) | HIF1AEPAS1COXFA4ALDH1A1CYP3A4 | |
| SCHEMBL30523641 | 0.72 | HIF1A (0.53) | HIF1AEPAS1 | |
| SCHEMBL9032078 | 0.72 | HIF1A (0.53) | HIF1AEPAS1COXFA4 | |
| SCHEMBL507142 | 0.72 | HIF1A (0.53) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273905-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | ABBOTT PRODUCTS GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| CN-101160301-B | Aminoalkyl-amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3, 4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers | SOLVAY PHARM BV | 2012-03-28 | — | — | CN | disclosed |
| EP-1871758-B1 | AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS | ABBOTT PRODUCTS GMBH (DE) | 2010-08-25 | — | — | EP | disclosed |
| US-7714150-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| CN-101160301-A | Aminoalkyl-amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3, 4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers | SOLVAY PHARM GMBH (DE) | 2008-04-09 | — | — | CN | disclosed |
| EP-1871758-A1 | AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS | Solvay Pharmaceuticals GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH | 2006-11-09 | — | — | US | disclosed |
| WO-2006108837-A1 | AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ABCC9 | HIF1A 2248/4885EPAS1 3765/4885HSP90AA1 2062/4885 |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ARG1 | HIF1A 2066/4885EPAS1 3930/4885HSP90AA1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.